PoD-TPI: Probability-of-Decision Toxicity Probability Interval Design to Accelerate Phase I Trials

04/29/2019
by   Tianjian Zhou, et al.
0

Cohort-based enrollment can slow down dose-finding trials since the outcomes of the previous cohort must be fully evaluated before the next cohort can be enrolled. This results in frequent suspension of patient enrollment. The issue is exacerbated in recent immune oncology trials where toxicity outcomes can take a long time to observe. We propose a novel phase I design, the probability-of-decision toxicity probability interval (PoD-TPI) design, to accelerate phase I trials. PoD-TPI enables dose assignment in real time in the presence of pending toxicity outcomes. With uncertain outcomes, the dose assignment decision is treated as a random variable, and we calculate the posterior distribution of the decision. The posterior distribution reflects the variability in the pending outcomes and allows a direct and intuitive evaluation of the confidence of all possible decisions. Optimal decisions are calculated based on 0-1 loss, and extra safety rules are constructed to enforce sufficient protection from exposing patients to risky doses. A new and useful feature of PoD-TPI is that it allows investigators to balance the trade-off between enrollment speed and making risky decisions by tuning a pair of intuitive design parameters. Through numerical studies, we evaluate the operating characteristics of PoD-TPI and demonstrate that PoD-TPI shortens trial duration and maintains desirable safety and efficiency compared to existing time-to-event designs.

READ FULL TEXT

page 1

page 2

page 3

page 4

research
03/10/2021

PoD-BIN: A Probability of Decision Bayesian Interval Design for Time-to-Event Dose-Finding Trials with Multiple Toxicity Grades

We consider a Bayesian framework based on "probability of decision" for ...
research
06/20/2020

A Unified Framework for Time-to-Event Dose-Finding Designs

In dose-finding trials, due to staggered enrollment, it might be desirab...
research
10/20/2020

Hi3+3: A Model-Assisted Dose-Finding Design Borrowing Historical Data

Background – In phase I clinical trials, historical data may be availabl...
research
07/23/2018

Time-to-Event Model-Assisted Designs to Accelerate Phase I Clinical Trials

Two useful strategies to speed up drug development are to increase the p...
research
10/01/2018

TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy

Immunotherapies have revolutionized cancer treatment. Unlike chemotherap...
research
01/04/2019

The i3+3 Design for Phase I Clinical Trials

Purpose: The 3+3 design has been shown to be less likely to achieve the ...
research
12/09/2020

What Were They Thinking? Pharmacologic priors implicit in a choice of 3+3 dose-escalation design

If explicit, formal consideration of clinical pharmacology at all inform...

Please sign up or login with your details

Forgot password? Click here to reset